Response to "assessment of risk of ALS conferred by the GGGGCC hexanucleotide expansion in C9orf72 among first-degree relatives of patients with ALS carrying the repeat expansion"

Laynie Dratch,Daniel D. Kinnamon,Elizabeth A. Harrington,Jill Goldman,Jamie C. Fong,Tara Jones,Wendy R. Uhlmann,Jennifer Roggenbuck
DOI: https://doi.org/10.1080/21678421.2024.2362854
2024-06-22
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Abstract:The authors DDK, EAH, JG, and WRU report there are no competing interests to declare. LD has consulted for Sano Genetics, Passage Bio, and Biogen. TJ holds shares in Invitae and Myriad, commercial genetic testing labs. JR has consulted for Biogen and Ionis. JCF has consulted for Alector, Inc.
clinical neurology
What problem does this paper attempt to address?